每日注射一次长效地特胰岛素:显著减少体重增加和低血糖发生

由丹麦诺和诺德公司生产的地特胰岛素(insulin detemir)是新一代长效人胰岛素类似物.地特胰岛素特有的作用延长机制使其控制血糖作用平稳而持久(可长达24 h),个体内和个体间的变异小,同时血糖控制水平的可预测性好.多项临床研究表明,与传统胰岛素相比,地特胰岛素在有效控制血糖的同时,低血糖(包括夜间低血糖)风险显著降低,并呈现出独特的较少增加体重的优势.上市后的观察性研究肯定了地特胰岛素良好的安全性和耐受性.本文就地特胰岛素的药理学特点及其在临床研究和应用方面的进展进行回顾.

Insulin detemir:A once-daily long-acting basal insulin analogue with clear weight and hypoglycaemia advantages

Insulin detemir is a new class of long-acting basal insulin analogue manufactured by Novo Nordisk A/S. The unique mechanism of protracted action designed for insulin detemir provides a stable and prolonged action of glycemic control up to 24 hours, reduced variability in glucose level, and a good predictable glucose profile. Many clinical trials demonstrated that subjects treated with insulin detemir achieved good glycemic control with a lower risk of experiencing hypoglycemic episodes and less weight gain compared with subjects treated by other basal insulin. The good safety and tolerability of insulin detemir is confirmed in postauthorization observational studies. This article reviews the pharmacologic characteristics of insulin detemir and the updates of its application in the clinical trials and routine practice.